INTERNATIONAL JOURNAL OF SOCIAL SCIENCES BULLETIN
ISSN: (E) 3007-1917 (P) 3007-1909
Volume 4, Issue 2, 2026

# COMPARATIVE EFFECTIVENESS OF COGNITIVE BEHAVIORAL THERAPY AND PHARMACOTHERAPY IN THE TREATMENT OF DEPRESSION: A META-ANALYTIC REVIEW

**Rimsha Moubeen[1], Umar Hayat Khan[2], Sameen Khalid[3], Qurat-Ul-Ain[*4], Huda Afzal[5]**

[1]*Riphah International University*
[2]*The Islamia University of Bahawalpur*
[3]*Multan Medical and Dental College*
[*4,5]*Department of Professional Psychology Bahria University Lahore Campus*

[1]rimshamoubeen@gmail.com, [2]school2ah@gmail.com, [3]sameenkhalid2001@gmail.com,
[*4]rajaquratulain@gmail.com"@gmail.com, [5]hudaafzal43@gmail.com

[2]ORCID ID: http://orcid.org/0009-0003-7109-3136
[*4]ORCID ID: https://orcid.org/0009-0002-1736-5535

**Corresponding Author: ***
**Qurat-Ul-Ain**
**DOI:** https://doi.org/10.5281/zenodo.18594106

| Received | Accepted | Published |
|---|---|---|
| 11 December 2025 | 26 January 2026 | 10 February 2026 |

## ABSTRACT

*Major Depressive Disorder (MDD) is among the most prevalent and disabling mental health conditions worldwide, contributing substantially to global disease burden and impaired quality of life. Cognitive Behavioral Therapy (CBT) and antidepressant pharmacotherapy are two of the most extensively researched and widely implemented evidence-based treatments for depression. Despite decades of research, debate continues regarding their relative effectiveness, speed of response, durability of treatment effects, and suitability for different patient populations. The present meta-analytic review synthesizes evidence from randomized controlled trials and existing meta-analyses that directly compare CBT and pharmacotherapy in the treatment of adult depression. Findings indicate that CBT and antidepressant medication demonstrate comparable efficacy in the acute treatment of depression, with no consistent superiority of one modality over the other. Pharmacotherapy may be associated with faster initial symptom relief, while CBT appears to confer greater long-term benefits, particularly in relapse prevention. Importantly, combined treatment frequently yields superior outcomes, especially for individuals with moderate to severe depressive symptoms. These findings underscore the importance of personalized treatment planning that incorporates symptom severity, patient preferences, and long-term outcomes.*

## INTRODUCTION

Major Depressive Disorder (MDD) is a leading cause of disability worldwide and represents a significant public health concern due to its high prevalence, recurrent course, and substantial personal and societal costs. The World Health Organization identifies depression as one of the top contributors to the global burden of disease, affecting more than 280 million people across

diverse cultural, social, and economic contexts (World Health Organization, 2021). Individuals with depression often experience persistent sadness, anhedonia, cognitive impairment, sleep disturbances, and functional disability, which can significantly interfere with occupational, academic, and interpersonal functioning. Furthermore, depression is associated with increased morbidity, mortality, and risk of suicide, underscoring the urgent need for effective and accessible treatments.

Among the most widely used evidence-based treatments for depression are Cognitive Behavioral Therapy (CBT) and antidepressant pharmacotherapy. CBT is a structured, time-limited psychological intervention grounded in the cognitive model of depression, which posits that maladaptive thought patterns and dysfunctional behaviors play a central role in the onset and maintenance of depressive symptoms (Beck, 1979). In contrast, pharmacotherapy primarily targets neurobiological mechanisms implicated in depression, such as monoamine dysregulation, through the use of medications including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, and other agents.

Although both CBT and pharmacotherapy have demonstrated efficacy in numerous clinical trials, comparative findings across studies have been inconsistent. Some investigations suggest equivalent outcomes, while others highlight differences in speed of response, relapse rates, and long-term effectiveness. Variability in study designs, sample characteristics, treatment duration, and outcome measures further complicates interpretation of individual studies. In this context, meta-analysis offers a powerful methodological approach for synthesizing findings across multiple studies, increasing statistical power, and providing more robust estimates of treatment effects.

Despite the availability of multiple empirically supported treatments for depression, treatment outcomes remain inconsistent, and a significant proportion of individuals fail to achieve full remission following initial intervention. Large-scale effectiveness studies suggest that approximately 30–40% of patients do not respond adequately to first-line treatments, regardless of whether psychotherapy or pharmacotherapy is employed (Rush et al., 2006). This substantial nonresponse rate has prompted ongoing efforts to better understand differential treatment effectiveness and to refine clinical decision-making in depression care.

A longstanding debate in the field concerns the conceptualization of depression itself, with competing psychological and biological models offering distinct explanations for its etiology and maintenance. Cognitive Behavioral Therapy (CBT) is grounded in cognitive and behavioral theories that emphasize the role of maladaptive beliefs, cognitive distortions, and behavioral avoidance in sustaining depressive symptoms (Beck, 2008). In contrast, pharmacotherapy is based on neurobiological models that implicate dysregulation of monoaminergic neurotransmitter systems, particularly serotonin and norepinephrine, in the pathophysiology of depression (Delgado, 2000). These differing theoretical orientations raise important questions regarding whether treatments that target psychological versus biological mechanisms yield different clinical outcomes.

Another critical issue in comparative treatment research involves the temporal course of therapeutic response. Pharmacotherapy is often assumed to produce more rapid symptom relief due to its direct effects on neurochemical processes, which may be particularly relevant in the acute phase of depression (Taylor et al., 2006). Psychotherapeutic interventions such as CBT, however, may require a longer period to produce measurable change, as they depend on the gradual modification of cognitive and behavioral patterns. Nonetheless, evidence suggests that once established, the benefits of CBT may persist beyond the end of treatment, raising questions about the relative importance of speed versus durability of response (DeRubeis et al., 2008).

Long-term outcomes, including relapse and recurrence, are especially salient given the episodic and recurrent nature of depressive disorders. Studies indicate that a majority of individuals who recover from a depressive episode will experience at least one recurrence during their lifetime

(Hardeveld et al., 2010). CBT has been hypothesized to reduce relapse risk by modifying cognitive vulnerabilities that predispose individuals to future episodes, a phenomenon often described as the "enduring effect" of psychotherapy (Hollon et al., 2006). In contrast, the benefits of pharmacotherapy appear to be closely tied to continued medication use, with discontinuation frequently associated with symptom return (Geddes et al., 2003).

Patient-related factors also play a crucial role in determining treatment effectiveness. Treatment preference, perceived acceptability, and adherence have all been shown to influence clinical outcomes in depression (Swift & Callahan, 2009). Some patients express reluctance toward long-term medication use due to concerns about side effects or dependence, while others may face barriers to accessing psychotherapy, such as cost or limited availability of trained clinicians. Research indicates that when patients receive their preferred treatment modality, they are more likely to remain engaged and show improved outcomes, underscoring the importance of integrating patient preferences into evidence-based care (Lindhiem et al., 2014).

Methodological heterogeneity across clinical trials further complicates comparisons between CBT and pharmacotherapy. Differences in therapist expertise, treatment fidelity, medication class and dosage, outcome measures, and follow-up duration contribute to variability in reported findings (Cuijpers et al., 2010). Additionally, many trials exclude patients with comorbid psychiatric or medical conditions, limiting the generalizability of results to real-world clinical populations. These methodological challenges highlight the need for meta-analytic approaches that can synthesize findings across diverse studies and provide more robust estimates of comparative effectiveness.

The present review aims to integrate and critically examine existing meta-analytic and randomized controlled trial evidence comparing CBT and pharmacotherapy in the treatment of depression. Specifically, this review focuses on acute treatment outcomes, long-term effectiveness, relapse prevention, and the added value of combined treatment approaches. By synthesizing the available evidence, this paper seeks to inform clinical decision-making and contribute to an evidence-based, patient-centered approach to depression treatment.

## Methods

The present study employed a meta-analytic review methodology to synthesize existing empirical literature comparing the effectiveness of CBT and pharmacotherapy in the treatment of depression. Rather than conducting a new quantitative meta-analysis, this review integrates findings from published meta-analyses and large-scale randomized controlled trials that directly compared these treatment modalities. This approach allows for a comprehensive examination of the broader evidence base while acknowledging methodological heterogeneity across individual studies.

Studies included in this review met several key criteria. First, only randomized controlled trials were considered, as this design provides the strongest evidence for causal inference regarding treatment effectiveness. Second, studies were required to directly compare CBT with antidepressant medication, either as standalone treatments or within combined treatment conditions. Third, participants were adults diagnosed with depressive disorders according to standardized diagnostic criteria such as the DSM or ICD. Finally, outcomes had to be assessed using validated and standardized depression measures, including instruments such as the Hamilton Depression Rating Scale (HDRS) and the Beck Depression Inventory (BDI).

Relevant literature was identified through searches of major academic databases, including PubMed, PsycINFO, and Google Scholar. In addition to primary studies, existing systematic reviews and meta-analyses were examined to ensure comprehensive coverage of the field. Key meta-analyses by Cuijpers and colleagues, DeRubeis and colleagues, and other leading researchers were given particular attention due to their methodological rigor and influence on clinical guidelines.

Primary outcomes of interest included reduction in depressive symptom severity, response rates, and remission rates during acute treatment.

Secondary outcomes included long-term maintenance of treatment gains, relapse and recurrence rates, and differential effects based on depression severity. While formal effect size calculations are not presented in this narrative review, effect size estimates reported in the original meta-analyses are discussed where relevant.

**Results**

Across the reviewed literature, both CBT and pharmacotherapy demonstrated substantial and clinically meaningful reductions in depressive symptoms. Meta-analytic findings consistently indicated that, on average, there is no statistically significant difference in overall efficacy between CBT and antidepressant medication in the acute treatment of depression. Cuijpers et al. (2013), in a comprehensive meta-analysis of randomized controlled trials, found comparable effect sizes for CBT and pharmacotherapy when each was compared to control conditions, suggesting that both treatments are equally effective in reducing depressive symptoms in the short term.

Several studies reported that antidepressant medication may produce more rapid symptom reduction, particularly in the early phases of treatment. This effect appears most pronounced for somatic symptoms such as sleep disturbances, appetite changes, and psychomotor retardation. DeRubeis et al. (2005) observed that patients receiving pharmacotherapy often experienced faster initial improvement than those receiving CBT, although differences tended to diminish over time as CBT effects accumulated.

In contrast, CBT was frequently associated with stronger maintenance of treatment gains following treatment termination. Multiple meta-analyses have shown that individuals treated with CBT are less likely to experience relapse after treatment discontinuation compared to those treated with medication alone (Hollon et al., 2005; Cuijpers et al., 2018). This durability effect is often attributed to the acquisition of cognitive and behavioral skills that enable patients to manage future stressors and prevent the reactivation of depressive thought patterns.

Importantly, combined treatment involving both CBT and pharmacotherapy consistently demonstrated superior outcomes compared to either treatment alone, particularly for individuals with moderate to severe depression. Meta-analytic evidence suggests that combined treatment yields higher response and remission rates, faster symptom reduction, and improved long-term outcomes (Thase et al., 1997; Cuijpers et al., 2014). These findings indicate that integrating psychological and pharmacological interventions may provide additive or synergistic benefits.

**Discussion**

The findings of this meta-analytic review support the conclusion that both CBT and pharmacotherapy are effective treatments for depression, with neither modality demonstrating consistent superiority across all outcome domains. The absence of a clear winner highlights the complexity of depression as a disorder and the need for flexible, individualized treatment approaches. Rather than framing CBT and pharmacotherapy as competing interventions, the evidence suggests that they address different but complementary aspects of depressive pathology.

CBT offers several distinct advantages, particularly with regard to relapse prevention and long-term outcomes. By targeting maladaptive cognitions and behaviors, CBT equips patients with skills that can be applied beyond the therapy context. These skills appear to confer protection against future depressive episodes, even after treatment has ended. This enduring effect is especially important given the recurrent nature of depression and the high risk of relapse following remission.

Pharmacotherapy, on the other hand, may be more accessible and faster-acting for some patients, particularly those with severe symptoms or limited access to psychotherapy. Medications can be prescribed in primary care settings and may be especially beneficial for individuals experiencing significant biological or somatic symptoms. However, long-term reliance on medication alone may be associated with higher relapse rates once treatment is discontinued.

The evidence supporting combined treatment is particularly compelling. For patients with moderate to severe depression, the integration of CBT and pharmacotherapy appears to optimize both short-term symptom relief and long-term

stability. Combined treatment may allow patients to benefit from the rapid symptom reduction associated with medication while simultaneously developing the coping skills fostered by CBT. Clinical guidelines increasingly recommend combined approaches for severe or treatment-resistant depression, reflecting this robust evidence base.

Despite its strengths, this review is limited by reliance on secondary sources and the inherent heterogeneity of the included studies. Variations in treatment protocols, therapist expertise, medication type and dosage, and outcome measures contribute to inconsistencies across findings. Additionally, many studies focus on short-term outcomes, underscoring the need for more long-term comparative research.

## Conclusion

In conclusion, both Cognitive Behavioral Therapy and pharmacotherapy are effective, evidence-based interventions for the treatment of depression. Meta-analytic evidence indicates that they are broadly comparable in acute treatment efficacy, with each offering unique advantages. CBT demonstrates particular strength in relapse prevention and long-term maintenance of gains, while pharmacotherapy may provide faster symptom relief and greater accessibility. Combined treatment consistently yields superior outcomes, especially for individuals with moderate to severe depression. Rather than viewing these treatments as mutually exclusive, clinicians should consider them as complementary options within a personalized, evidence-based framework that prioritizes patient preferences, symptom severity, and long-term recovery.

## References

Beck, A. T. (1979). *Cognitive therapy of depression*. Guilford Press.

Beck, A. T. (2008). The evolution of the cognitive model of depression and its neurobiological correlates. *American Journal of Psychiatry, 165*(8), 969–977. https://doi.org/10.1176/appi.ajp.2008.08050721

Cuijpers, P., Andersson, G., Donker, T., & van Straten, A. (2011). Psychological treatment of depression: Results of a series of meta-analyses. *Nordic Journal of Psychiatry, 65*(6), 354–364. https://doi.org/10.3109/08039488.2011.596570

Cuijpers, P., Berking, M., Andersson, G., Quigley, L., Kleiboer, A., & Dobson, K. S. (2013). A meta-analysis of cognitive-behavioural therapy for adult depression, alone and in comparison with other treatments. *Canadian Journal of Psychiatry, 58*(7), 376–385. https://doi.org/10.1177/070674371305800702

Cuijpers, P., Noma, H., Karyotaki, E., Cipriani, A., & Furukawa, T. A. (2018). Effectiveness and acceptability of cognitive behavior therapy delivery formats in adults with depression: A network meta-analysis. *World Psychiatry, 17*(2), 186–195. https://doi.org/10.1002/wps.20519

Cuijpers, P., van Straten, A., Andersson, G., & van Oppen, P. (2008). Psychotherapy for depression in adults: A meta-analysis of comparative outcome studies. *Journal of Consulting and Clinical Psychology, 76*(6), 909–922. https://doi.org/10.1037/a0013075

Cuijpers, P., van Straten, A., Hollon, S. D., & Andersson, G. (2008). The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: A meta-analysis of direct comparisons. *World Psychiatry, 7*(3), 181–188.

Cuijpers, P., van Straten, A., Warmerdam, L., & Andersson, G. (2010). Psychological treatment of depression: A meta-analytic database of randomized studies. *BMC Psychiatry, 10*, Article 77. https://doi.org/10.1186/1471-244X-10-77

Cuijpers, P., van Straten, A., Hollon, S. D., Andersson, G., & Noma, H. (2014). Combining pharmacotherapy and psychotherapy or monotherapy for major depression? A meta-analysis of comparative studies. *World Psychiatry, 13*(1), 56–67. https://doi.org/10.1002/wps.20092

Delgado, P. L. (2000). Depression: The case for a monoamine deficiency. *Journal of Clinical Psychiatry, 61*(Suppl 6), 7–11.

DeRubeis, R. J., Hollon, S. D., Amsterdam, J. D., Shelton, R. C., Young, P. R., Salomon, R. M., Gallop, R. (2005). Cognitive therapy vs medications in the treatment of moderate to severe depression. *Archives of General Psychiatry, 62*(4), 409–416. https://doi.org/10.1001/archpsyc.62.4.409

DeRubeis, R. J., Siegle, G. J., & Hollon, S. D. (2008). Cognitive therapy versus medication for depression: Treatment outcomes and neural mechanisms. *Nature Reviews Neuroscience, 9*(10), 788–796. https://doi.org/10.1038/nrn2345

Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003). Relapse prevention with antidepressant drug treatment in depressive disorders: A systematic review. *The Lancet, 361*(9358), 653–661. https://doi.org/10.1016/S0140-6736(03)12599-8

Hollon, S. D., Stewart, M. O., & Strunk, D. (2006). Enduring effects for cognitive behavior therapy in the treatment of depression and anxiety. *Annual Review of Psychology, 57*, 285–315. https://doi.org/10.1146/annurev.psych.57.102904.190044

Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Fava, M. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. *American Journal of Psychiatry, 163*(11), 1905–1917. https://doi.org/10.1176/ajp.2006.163.11.1905

Swift, J. K., & Callahan, J. L. (2009). The impact of client treatment preferences on outcome: A meta-analysis. *Journal of Clinical Psychology, 65*(4), 368–381. https://doi.org/10.1002/jclp.20553

Taylor, M. J., Freemantle, N., Geddes, J. R., & Bhagwagar, Z. (2006). Early onset of selective serotonin reuptake inhibitor antidepressant action: Systematic review and meta-analysis. *Archives of General Psychiatry, 63*(11), 1217–1223. https://doi.org/10.1001/archpsyc.63.11.1217

World Health Organization. (2021). *Depression*. https://www.who.int/news-room/fact-sheets/detail/depression

IEER
Institute for Excellence in Education & Research